We don't want to downplay the importance of the FDA's decision to place PledOx on clinical hold in the US, however, as long as the DSMB continues to recommend a continuation of the POLAR program, we believe the decision could be of a temporary nature. We continue to be positive about the current valuation of Pledpharma. Still, we expect the share price to remain under pressure until we get further clarity from the FDA (likely to happen in the next 1-3 months).